التفاصيل البيبلوغرافية
| العنوان: |
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis |
| المؤلفون: |
Melissa M. De Meza, Willeke A. M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. Van Not, Djura Piersma, Rozemarijn S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. Van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. Van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters |
| المصدر: |
Cancers; Volume 15; Issue 2; Pages: 409 |
| بيانات النشر: |
Multidisciplinary Digital Publishing Institute |
| سنة النشر: |
2023 |
| المجموعة: |
MDPI Open Access Publishing |
| مصطلحات موضوعية: |
melanoma, adjuvant therapy, targeted therapy, immune checkpoint inhibition |
| الوصف: |
Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RFS) compared to placebo in resected stage III BRAF-mutant melanoma. However, data beyond the clinical trial setting are limited. This study describes the toxicity and survival of patients treated with adjuvant BRAF/MEK inhibitors and compares outcomes to adjuvant anti-PD-1. For this study, stage III BRAF V600 mutant cutaneous melanoma patients treated with adjuvant BRAF/MEK-inhibition or anti-PD-1 were identified from the Dutch Melanoma Treatment Registry. BRAF/MEK- and anti-PD-1-treated patients were matched based on propensity scores, and RFS at 12 and 18 months were estimated. Between 1 July 2018 and 31 December 2021, 717 patients were identified. Of these, 114 patients with complete records were treated with BRAF/MEK therapy and 532 with anti-PD-1. Comorbidities (p = 0.04) and geographical region (p < 0.01) were associated with treatment choice. In 45.6% of BRAF/MEK-treated patients, treatment was prematurely discontinued. Grade ≥ 3 toxicity occurred in 11.5% of patients and was the most common cause of early discontinuation (71.1%). At 12 and 18 months, RFS in BRAF/MEK-treated patients was 85% and 70%, compared to 68% and 68% in matched anti-PD-1-treated patients (p = 0.03). In conclusion, comorbidities and geographical region determine the choice of adjuvant treatment in patients with resected stage III BRAF-mutant melanoma. With the currently limited follow-up, BRAF/MEK-treated patients have better RFS at 12 months than matched anti-PD-1-treated patients, but this difference is no longer observed at 18 months. Therefore, longer follow-up data are necessary to estimate long-term effectiveness. |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
Cancer Immunology and Immunotherapy; https://dx.doi.org/10.3390/cancers15020409Test |
| DOI: |
10.3390/cancers15020409 |
| الإتاحة: |
https://doi.org/10.3390/cancers15020409Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.7DCC7966 |
| قاعدة البيانات: |
BASE |
